9-氨基喜樹堿
| 中文名稱 | 9-氨基喜樹堿 |
|---|---|
| 中文同義詞 | 9-氨基喜樹堿;(S)-10-氨基-4-乙基-4-羥基-1H-吡喃并[3',4':6,7]1-吲哚啉嗪O[1,2-B]喹啉-3,14(4H,12H)-二酮;9-氨基喜樹堿,(20S)-9-氨基喜樹堿;9-AMINOCAMPTOTHECIN 9-氨基喜樹堿;9-氨基喜樹堿 250MG;(20S)-9-氨基喜樹堿;9-氨基喜樹堿, >96%;9-氨基喜樹堿 標(biāo)準(zhǔn)品 |
| 英文名稱 | 9-Aminocamptothecin |
| 英文同義詞 | 4':6,7)indolizino(1,2-B)quinoline-3,14(4H,12H)-dione;4':6,7)indolizino(1,2-B)quinoline-3,14(4H,12H)-dione, 10-amino-4-ethyl-4-hydroxy-, (S)-;CAMPTOTHECIN, 9-AMINO-(RG);(S)-10-AMino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-10-Amino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-di;CAMPTOTHECIN, 9-AMINO-;AMinocaMptothecin;9-AMINO-CAMPTOTHECIN |
| CAS號(hào) | 91421-43-1 |
| 分子式 | C20H17N3O4 |
| 分子量 | 363.37 |
| EINECS號(hào) | |
| 相關(guān)類別 | 化學(xué)連接;中藥對(duì)照品;喜樹堿系列;植物提取物;標(biāo)準(zhǔn)品;細(xì)胞生物學(xué)試劑;分析試劑標(biāo)準(zhǔn)品;Pharmaceutical Raw Materials;Alkaloids;Natural Anti-cancer Medical Materials and It's Derivatives;對(duì)照品-中藥對(duì)照品;對(duì)照品;標(biāo)準(zhǔn)品 -中藥標(biāo)準(zhǔn)品;醫(yī)藥原料藥;醫(yī)藥、農(nóng)藥及染料中間體;標(biāo)準(zhǔn)品，對(duì)照品 |
| Mol文件 | 91421-43-1.mol |
| 結(jié)構(gòu)式 |  |
9-氨基喜樹堿 性質(zhì)
| 熔點(diǎn) | 142.0-145.0 °C |
|---|---|
| 沸點(diǎn) | 819.6±65.0 °C(Predicted) |
| 密度 | 1.55±0.1 g/cm3(Predicted) |
| 儲(chǔ)存條件 | 2-8°C(protect from light) |
| 溶解度 | DMSO 中≤1mg/ml；二甲基甲酰胺中≤1mg/ml |
| 形態(tài) | 粉末晶體 |
| 酸度系數(shù)(pKa) | 11.23±0.20(Predicted) |
| 顏色 | 淡黃色至黃色至橙色 |
| Merck | 14,431 |
| InChI | InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1 |
| InChIKey | FUXVKZWTXQUGMW-FQEVSTJZSA-N |
| SMILES | N1C2C(=C(N)C=CC=2)C=C2CN3C(C=12)=CC1[C@](CC)(O)C(=O)OCC=1C3=O |
| CAS 數(shù)據(jù)庫(kù) | 91421-43-1(CAS DataBase Reference) |
| Target | Value |
|
Topo I
() |
In human breast (MCF-7), bladder (MGH-U1), and colon (HT-29) cancer cell lines, 9-Aminocamptothecin cytotoxicity increases with both higher drug concentrations and longer exposure times. Minimal cell killing is also observed unless 9-Aminocamptothecin concentrations exceeds a threshold of 2.7 nm. 9-Aminocamptothecin inhibits PC-3, PC-3M, DU145, and LNCaP cells with IC 50 values of 34.1, 10, 6.5, and 8.9 nM, respectively after 96 h of drug exposure.
9-amino-CPT (9-amino-20(S)-camptothecin) inhibits tumor growth at the lowest oral dose (0.35 mg/kg/day), whereas higher oral doses (0.75 and 1 mg/kg/day) and s.c. administration (4 mg/kg/week) causes tumor regression. 9-amino-CPT (9-amino-20(S)-camptothecin) is well tolerated at all doses, with no toxic death or weight loss of more than 10% observed in any group. 9-amino-CPT (9-amino-20(S)-camptothecin) induces complete remissions in 55 % of SCID mice engrafted with human myeloid leukemia. The oral and intravenous routes are equally effective. The results with this pre-clinical model support the evaluation of 9-Aminocamptothecin as antileukemic agent in a phase I trial in patients with AML.
藥理藥效:抗腫瘤
安全信息
| RTECS號(hào) | UQ0490500 |
|---|---|
| 海關(guān)編碼 | 29349990 |
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-100309 | 9-氨基喜樹堿 9-Aminocamptothecin | 91421-43-1 | 1 mg | 429元 |
| 2025/05/22 | HY-100309 | 9-氨基喜樹堿 9-Aminocamptothecin | 91421-43-1 | 2 mg | 600元 |